Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

Sunday, November 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology reported positive topline results from its Phase 3 ECLIPSE 1 trial. The trial evaluated the monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta. Results were presented at the AASLD The Liver Meeting 2026 in Denver, Colorado, indicating a successful outcome.

Market Sentiment Analysis

POSITIVE FACTORS

  • Primary endpoint met in pivotal Phase 3 trial.
  • Positive topline results reported.
  • Presented at a significant medical conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Cash runway
~13 mo
Medium dilution risk
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration of elebsiran and tobevibart in adults with chronic hepatitis delta (CHD). Topline results were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026, in Denver, Colorado. “For people living with CHD, the goal is not simply to reduce

Frequently Asked Questions

What was the outcome of the ECLIPSE 1 trial?

The ECLIPSE 1 trial met its primary endpoint with positive topline results.

Where were the trial results presented?

Results were presented at the AASLD The Liver Meeting 2026 in Denver.

What treatments were evaluated in the trial?

The trial evaluated elebsiran and tobevibart for chronic hepatitis delta.

What is the significance of the ECLIPSE 1 trial?

It is a pivotal trial for treating chronic hepatitis delta in adults.

ShareAdd on Google
Tags: VIR Vir Biotechnology elebsiran tobevibart chronic hepatitis delta AASLD
Last updated: Nov 8, 2026

Biotech snapshot

Cash runway
$455M liquidity · $35M/mo burn
~13 mo
Medium dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →